RGS2 has been shown to suppress oncogenic signaling by inhibiting the phosphorylation of ERK and AKT (19, 33) This mechanism is particularly evident in colon tumors, where ERK and AKT phosphorylation are critical regulatory events driving malignant transformation and cancer cell behavior (34, 35). This evidence concerns the gene RGS2 and cancer.